UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant.

A multicenter team of childhood cancer researchers has discovered two genetic variations linked to an increased risk for acute lymphoblastic leukemia, or ALL, the most common childhood cancer in the United States.

A new study shows that certain genes are turned off early, before clinical signs of the disease appear, in the development of chronic leukemia.

One of the most bothersome symptoms of leukemia is extreme fatigue, and asking these patients to exercise doesn't sound like a way to help them feel better.

Each year, approximately 4,500 children in America are diagnosed with leukemia, according to the Leukemia and Lymphoma Society. A potentially deadly cancer of the blood, it is the most common cancer in children.

Dr. Richard Lock is leading the clinical trial in Australia that expands on research suggesting that antibodies targeting cancer stem cells significantly reduced the growth of human acute myeloid leukemia cells that had been transplanted into immune-deficient mice, a laboratory model that mimics the human disease, establishing the therapeutic potential of this type of therapy.

New research describes a molecular tool that shows great promise as a therapeutic for human acute myeloid leukemia (AML), a notoriously treatment-resistant blood cancer. The study, published by Cell Press in the July 2nd issue of the journal Cell Stem Cell, describes exciting preclinical studies in which a new therapeutic approach selectively attacks human cancer cells grown in the lab and in animal models of acute myeloid leukemia.

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered how to turn off a certain receptor that promotes the growth of leukemia cells.

Scientists at the University of California, San Diego and the Moores UCSD Cancer Center have evidence of a potential new biomarker to predict the aggressiveness of an often difficult-to-treat form of leukemia.

The inactivity or “silence” of certain genes plays a fundamental role in the prognosis of acute lymphoblastic leukemia (ALL) as well as in response to treatment, according to the results of research involving a team made up of specialists from the University Hospital of Navarra and the Centre for Applied Medical Research (CIMA) at the same University of Navarra, as well as the Reina Sofía Hospital in Córdoba, Andalusia.

An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky. They found that within 24 hours, 76 percent of leukemia cells had died after being exposed to the extract.